AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36322381 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscosity (gel and liquid)
Number of subjects: 96
Study 34563112 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye mask (masked group, n=20)
Number of subjects: 38
Study 34563112 — intervention group
Group type: COMPARATOR
Intervention: No eye mask (control group, n=18)
Number of subjects: 38
Study 36031005 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory reactivation under propranolol (25mg)
Number of subjects: 61
Study 34372670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat, 22% monounsaturated fatty acids, <50% carbohydrates)
Number of subjects: 1002
Study 34372670 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (28% fat, 12% monounsaturated fatty acids, >55% carbohydrates)
Number of subjects: 1002
Study 34372670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1002
Study 32706660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3D virtual reality and hands-on aromatherapy
Number of subjects: 60
Study 32706660 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 35633354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g intravenously) given 12 hr. before skin incision (Group 2)
Number of subjects: 150
Study 35633354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g intravenously) given 12 hr. after operation (Group 3)
Number of subjects: 150
Study 35633354 — intervention group
Group type: COMPARATOR
Intervention: Normal saline given 12 hr. before and after skin incision (Control Group 1)
Number of subjects: 150
Study 34228855 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐interferon alpha add-on with Tenofovir disoproxil fumarate (TDF) for 48 weeks followed by TDF alone for 48 weeks
Number of subjects: 133
Study 34228855 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) monotherapy for 96 weeks
Number of subjects: 133
Study 34228855 — intervention group
Group type: COMPARATOR
Intervention: TDF alone for 48 weeks and sequentially Peg‐IFNα added for 48 weeks
Number of subjects: 133
Study 32275363 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal penetration on acupoint combined with medication (oral prednisone tablets for 40 days, starting with 10 mg three times a day, reducing by 5 mg every 7 days)
Number of subjects: 72
Study 32275363 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal penetration on acupoint
Number of subjects: 72
Study 34369837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg/day for 8 weeks
Number of subjects: 60
Study 34910809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and cognitive training (PTCT)
Number of subjects: 314
Study 34910809 — intervention group
Group type: COMPARATOR
Intervention: Physical training (PT)
Number of subjects: 314
Study 32922107 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery-based smoking cessation intervention (details on dosage and duration not available)
Number of subjects: 51
Study 32922107 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery-based smoking cessation intervention
Number of subjects: 51
Study 34436812 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 72
Study 34436812 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 72
Study 34436812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study 32019981 — intervention group
Group type: EXPERIMENTAL
Intervention: End-effector (EE) robot
Number of subjects: 38
Study 32019981 — intervention group
Group type: COMPARATOR
Intervention: Exoskeleton (Exo) robot
Number of subjects: 38
Study 34157879 — intervention group
Group type: EXPERIMENTAL
Intervention: Small low proliferation cancers (SLPC) in the research series (n=534)
Number of subjects: 8967
Study 34157879 — intervention group
Group type: EXPERIMENTAL
Intervention: Small low proliferation cancers (SLPC) in the registry series (n=8433)
Number of subjects: 8967
Study 34333826 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (6-fold of MED as initial dose)
Number of subjects: 77
Study 34333826 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (4-fold of MED as initial dose)
Number of subjects: 77
Study 34333826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (2-fold of MED as initial dose)
Number of subjects: 77
Study 34808687 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleultrasound
Number of subjects: 300
Study 34808687 — intervention group
Group type: COMPARATOR
Intervention: Standard in-person ultrasound
Number of subjects: 300
Study 33233946 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure blow‐bottle device (G2)
Number of subjects: 48
Study 33233946 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory positive airway pressure (G3)
Number of subjects: 48
Study 33233946 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (G1)
Number of subjects: 48
Study 32561903 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet interventions
Number of subjects: 184
Study 32561903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 184
Study 33877376 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Number of subjects: 238
Study 33877376 — intervention group
Group type: COMPARATOR
Intervention: Office-based follow-up
Number of subjects: 238
Study 32969222 — intervention group
Group type: EXPERIMENTAL
Intervention: Block randomization
Number of subjects: 0
Study 32969222 — intervention group
Group type: COMPARATOR
Intervention: Complete randomization
Number of subjects: 0
Study 33333771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution (DD) - carbohydrates: 33 g·L‐1, sodium: 60 ± 3 mmol·L‐1
Number of subjects: 9
Study 33333771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports Drink (SD) - carbohydrates: 62 g·L‐1, sodium: 31 ± 3 mmol·L‐1
Number of subjects: 9
Study 33333771 — intervention group
Group type: COMPARATOR
Intervention: Water (WA)
Number of subjects: 9
Study 36175936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate Ringer’s solution (BRS)
Number of subjects: 400
Study 36175936 — intervention group
Group type: COMPARATOR
Intervention: Sodium lactate Ringer’s solution
Number of subjects: 400
Study 33480665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 138
Study 33480665 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) cephalosporin
Number of subjects: 138
Study 33228549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening in high-risk areas
Number of subjects: 149956
Study 33228549 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic screening in non-high-risk areas
Number of subjects: 149956
Study 35458222 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-biofortified flour
Number of subjects: 517
Study 35458222 — intervention group
Group type: COMPARATOR
Intervention: Control flour
Number of subjects: 517
Study 33208019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette Smoking (CS)
Number of subjects: 36
Study 33208019 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Cigarettes (EC)
Number of subjects: 36
Study 33208019 — intervention group
Group type: COMPARATOR
Intervention: No Tobacco Product
Number of subjects: 36
Study 35297463 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated exercise intervention for 12 months
Number of subjects: 146
Study 35297463 — intervention group
Group type: COMPARATOR
Intervention: Control group continued daily activities
Number of subjects: 146
Study 34977248 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 discharge after uncomplicated CS
Number of subjects: 228
Study 34101713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine 50 mg
Number of subjects: 40
Study 34101713 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 10 mg
Number of subjects: 40
Study 33113277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, daily)
Number of subjects: 120
Study 33113277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg, OD)
Number of subjects: 120
Study 33113277 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg, OD)
Number of subjects: 120
Study 33113277 — intervention group
Group type: COMPARATOR
Intervention: Dapoxetine (30 mg, OD)
Number of subjects: 120
Study 34898273 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Number of subjects: 30
Study 34898273 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 30
Study 32316009 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural therapy (n = 52)
Number of subjects: 113
Study 32316009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neural therapy, n = 61)
Number of subjects: 113
Study 35263859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous selenium selenite for 5 days
Number of subjects: 44
Study 35263859 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as placebo
Number of subjects: 44
Study 35263859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium selenite
Number of subjects: 44
Study 33539729 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy in 12 fractions
Number of subjects: 548
Study 33539729 — intervention group
Group type: COMPARATOR
Intervention: 4 Gy in two fractions
Number of subjects: 548
Study 33539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for 24 Gy
Number of subjects: 548
Study 33539729 — intervention group
Group type: COMPARATOR
Intervention: Adverse events for 4 Gy
Number of subjects: 548
Study 34973513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Number of subjects: 340
Study 34973513 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Number of subjects: 340
Study 34089321 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Calibration Modeling (GCM)
Number of subjects: 0
Study 34089321 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Multicomponent Multivariate Modeling (RMMM)
Number of subjects: 0
Study 34089321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of GCM and RMMM
Number of subjects: 0
Study 32524500 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously
Number of subjects: 196
Study 32524500 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 196
Study 32524500 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 196
Study 32524500 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 196
Study 34076068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg IV) in addition to propofol anesthesia for ECT
Number of subjects: 45
Study 34076068 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia for ECT
Number of subjects: 45
Study 33788463 — intervention group
Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with mifepristone (10 mg once a day) for 3 months
Number of subjects: 70
Study 33788463 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (10 mg once a day) for 3 months
Number of subjects: 70
Study 36101809 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based nursing intervention
Number of subjects: 80
Study 36101809 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nursing care)
Number of subjects: 80
Study 32421612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based compassionate living (MBCL)
Number of subjects: 122
Study 32421612 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 122
Study 34144908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group self-management education intervention
Number of subjects: 70
Study 34144908 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 70
Study 34144908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity assessment of the intervention
Number of subjects: 70
Study 34144908 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 70
Study 34144908 — intervention group
Group type: EXPERIMENTAL
Intervention: Private Facebook group
Number of subjects: 70
Study 33539573 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-histology
Number of subjects: 569
Study 33539573 — intervention group
Group type: COMPARATOR
Intervention: Serial section histology
Number of subjects: 569
Study 32188310 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support in primary care (intervention group, IG)
Number of subjects: 271
Study 32188310 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up in cardiology outpatient clinic (control group, CG)
Number of subjects: 271
Study 32375572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus Terrestris (TT)
Number of subjects: 18
Study 32375572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 18
Study 36219978 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (early‐PN)
Number of subjects: 1247
Study 36219978 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (late‐PN)
Number of subjects: 1247
Study 36219978 — intervention group
Group type: EXPERIMENTAL
Intervention: Early RFH
Number of subjects: 1247
Study 36219978 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition intake
Number of subjects: 1247
Study 33606931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg bid)
Number of subjects: 21
Study 33606931 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg bid)
Number of subjects: 21
Study 33606931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 35872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/(kg·h)
Number of subjects: 495
Study 35872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/(kg·h)
Number of subjects: 495
Study 35872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 μg/(kg·h)
Number of subjects: 495
Study 35872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8 μg/(kg·h) in group A3
Number of subjects: 495
Study 33676882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids (7-day course) + nasal steroids and douching (12-week course)
Number of subjects: 140
Study 33676882 — intervention group
Group type: COMPARATOR
Intervention: Nasal steroids and douching (12-week course)
Number of subjects: 140
Study 34721571 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning with cathodal HD-tDCS
Number of subjects: 24
Study 34721571 — intervention group
Group type: COMPARATOR
Intervention: Sham cathodal HD-tDCS preconditioning
Number of subjects: 24
Study 33187532 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training (45 min, five times per week over 3 weeks)
Number of subjects: 60
Study 33187532 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (45 min, five times per week over 3 weeks)
Number of subjects: 60
Study 33573598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone for PCIA + transmuscular quadratus lumborum block
Number of subjects: 80
Study 33573598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone for PCIA
Number of subjects: 80
Study 33573598 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil for PCIA
Number of subjects: 80
Study 36280159 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized tourniquet
Number of subjects: 127
Study 36280159 — intervention group
Group type: COMPARATOR
Intervention: Without tourniquet
Number of subjects: 127
Study 34884387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial lung cryobiopsy (TBLC)
Number of subjects: 359
Study 34884387 — intervention group
Group type: COMPARATOR
Intervention: Transbronchial forceps biopsy (TBLF)
Number of subjects: 359
Study 32979512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg on day 1) and nab-paclitaxel (125 mg/m2 on day 1 and day 8, every 3 weeks)
Number of subjects: 70
Study 35525251 — intervention group
Group type: EXPERIMENTAL
Intervention: tenecteplase (0·25 mg/kg, maximum 25 mg, intravenous bolus over 10 s)
Number of subjects: 104
Study 35525251 — intervention group
Group type: COMPARATOR
Intervention: alteplase (0·9 mg/kg, maximum 90 mg, 10% as bolus over 1 min and 90% as infusion over 1 h)
Number of subjects: 104
Study 35525251 — intervention group
Group type: EXPERIMENTAL
Intervention: tenecteplase
Number of subjects: 104
Study 35525251 — intervention group
Group type: COMPARATOR
Intervention: alteplase
Number of subjects: 104
Study 32416333 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent hybrid procedure
Number of subjects: 153
Study 32416333 — intervention group
Group type: COMPARATOR
Intervention: Endocardial catheter ablation
Number of subjects: 153
Study 35231024 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up (n=1,976)
Number of subjects: 3945
Study 35231024 — intervention group
Group type: COMPARATOR
Intervention: Weekly follow-up (n=1,802)
Number of subjects: 3945
Study 35231024 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up (n=976)
Number of subjects: 3945
Study 35231024 — intervention group
Group type: COMPARATOR
Intervention: Weekly follow-up (n=1,005)
Number of subjects: 3945
Study 35231024 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up (n=1,873)
Number of subjects: 3945
Study 35231024 — intervention group
Group type: COMPARATOR
Intervention: Weekly follow-up (n=1,721)
Number of subjects: 3945
Study 32472590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TACE and sorafenib
Number of subjects: 64
Study 32472590 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (monotherapy group)
Number of subjects: 64
Study 33178135 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-Ex (45 min of cycling exercise after 3.5 h of normoglycemia)
Number of subjects: 12
Study 33178135 — intervention group
Group type: EXPERIMENTAL
Intervention: HG-Ex (45 min of cycling exercise after 3.5 h of steady-state hyperglycemia)
Number of subjects: 12
Study 33178135 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-Ex (45 min of cycling exercise after 3.5 h of fluctuating hyperglycemia)
Number of subjects: 12
Study 33178135 — intervention group
Group type: COMPARATOR
Intervention: CON (no exercise)
Number of subjects: 12
Study 34560112 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg each, 2 tablets, total 6 mg)
Number of subjects: 64
Study 33476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges (1:1 savings match rate)
Number of subjects: 1383
Study 33476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges PLUS (2:1 savings match rate)
Number of subjects: 1383
Study 33476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges
Number of subjects: 1383
Study 33476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges PLUS
Number of subjects: 1383
Study 33476237 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1383
Study 32203751 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 157
Study 32203751 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 157
Study 35991150 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL combined with situational simulation teaching method
Number of subjects: 120
Study 34162631 — intervention group
Group type: EXPERIMENTAL
Intervention: HamRaah (mHealth intervention)
Number of subjects: 0
Study 34162631 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 0
Study 32532564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided ankle block
Number of subjects: 0
Study 32532564 — intervention group
Group type: COMPARATOR
Intervention: Blind local infiltration
Number of subjects: 0
Study 35389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norming messages
Number of subjects: 391
Study 35389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal messages
Number of subjects: 391
Study 35389364 — intervention group
Group type: COMPARATOR
Intervention: Control group messages
Number of subjects: 391
Study 35389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal messages (subgroup analysis)
Number of subjects: 391
Study 35389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norming messages (subgroup analysis)
Number of subjects: 391
Study 35389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norming messages (among consistent wearers at baseline)
Number of subjects: 391
Study 34684528 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 491
Study 34684528 — intervention group
Group type: COMPARATOR
Intervention: Non-PCOS group
Number of subjects: 491
Study 33362194 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference cutoff of 90 cm in men
Number of subjects: 3387
Study 33362194 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference cutoff of 86 cm in women
Number of subjects: 3387
Study 33362194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of abdominal obesity
Number of subjects: 3387
Study 35149320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of fiber
Number of subjects: 1521
Study 35149320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of magnesium
Number of subjects: 1521
Study 35149320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of niacin
Number of subjects: 1521
Study 35149320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of thiamine
Number of subjects: 1521
Study 35149320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of folate
Number of subjects: 1521
Study 33961650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis (TB) cohort
Number of subjects: 6934
Study 33961650 — intervention group
Group type: COMPARATOR
Intervention: No Tuberculosis (TB) exposure (control cohort)
Number of subjects: 6934
Study 33961650 — intervention group
Group type: EXPERIMENTAL
Intervention: TB cohort
Number of subjects: 6934